RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
CardioGenics Holdings - Stock

CardioGenics Holdings ROCE 2024

CardioGenics Holdings ROCE

0

CardioGenics Holdings Dividend yield

Ticker

CGNH

ISIN

US14160X2036

WKN

A1C048

In 2024, CardioGenics Holdings's return on capital employed (ROCE) was 0, a 0% increase from the 0 ROCE in the previous year.

CardioGenics Holdings Aktienanalyse

What does CardioGenics Holdings do?

The company CardioGenics Holdings Inc. is headquartered in Mississauga, Canada, and is a leading company in the field of cardiovascular disease diagnostics. The company was founded in 1997 by Walter Witoshkin, who continues to serve as CEO today. CardioGenics' business model is based on the development and marketing of solutions for fast, reliable, and cost-effective diagnosis of cardiovascular diseases. The focus is especially on the diagnosis of heart attacks and heart failure. To achieve these goals, CardioGenics has developed various divisions. The most important division is the production of in-vitro diagnostics (IVD). These are tests that are performed based on blood samples, enabling doctors to make a quick and easy diagnosis. Another important area of CardioGenics is the development of diagnostics based on immunassays. Antibodies are used to identify specific proteins in the blood that indicate a certain disease. This allows early predictions about the risk of cardiovascular diseases. In addition to the development of diagnostics, CardioGenics is also active in the field of research and development. The company works closely with academic institutions and research partners to develop and market innovative solutions in the field of diagnostics. CardioGenics' products include various IVD tests specifically developed for the diagnosis of cardiovascular diseases. One of the most important products is the QL Care Analyzer, a fully automated system for the rapid determination of Troponin I, a protein released in the blood during heart attacks. Another important product of CardioGenics is the Myo9 test. This test is an immunassay that allows doctors to determine the risk of cardiovascular diseases in certain patient groups. The test is mainly used for patients with diabetes, as they have an increased risk of cardiovascular diseases. Furthermore, CardioGenics also offers various services such as training and user support for its products. The company works closely with customers to provide them with the best possible support in the application of IVD tests and other diagnostic products. In recent years, CardioGenics has expanded its business internationally and launched its products in various countries. The company also has a strong presence at leading scientific conferences and trade fairs to showcase its products and services and share its expertise in the field of cardiovascular diagnostics. In summary, CardioGenics is an established company in the field of cardiovascular disease diagnostics. With a wide range of diagnostic products and a strong focus on research and development, the company is well positioned to continue growing and strengthen its presence in the international market. CardioGenics Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling CardioGenics Holdings's Return on Capital Employed (ROCE)

CardioGenics Holdings's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing CardioGenics Holdings's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

CardioGenics Holdings's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in CardioGenics Holdings’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about CardioGenics Holdings Stock

What is the ROCE (Return on Capital Employed) of CardioGenics Holdings this year?

The ROCE of CardioGenics Holdings is 0 undefined this year.

How has the ROCE (Return on Capital Employed) of CardioGenics Holdings developed compared to the previous year?

The ROCE of CardioGenics Holdings has increased by 0% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of CardioGenics Holdings?

A high Return on Capital Employed (ROCE) indicates that CardioGenics Holdings has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of CardioGenics Holdings?

A low ROCE (Return on Capital Employed) can indicate that CardioGenics Holdings has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from CardioGenics Holdings impact the company?

An increase in the ROCE of CardioGenics Holdings can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of CardioGenics Holdings affect the company?

A decrease in ROCE of CardioGenics Holdings can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of CardioGenics Holdings?

Some factors that can affect CardioGenics Holdings's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of CardioGenics Holdings so important for investors?

The ROCE of CardioGenics Holdings is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can CardioGenics Holdings take to improve the ROCE?

To improve the ROCE, CardioGenics Holdings can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does CardioGenics Holdings pay?

Over the past 12 months, CardioGenics Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CardioGenics Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of CardioGenics Holdings?

The current dividend yield of CardioGenics Holdings is .

When does CardioGenics Holdings pay dividends?

CardioGenics Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of CardioGenics Holdings?

CardioGenics Holdings paid dividends every year for the past 0 years.

What is the dividend of CardioGenics Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is CardioGenics Holdings located?

CardioGenics Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von CardioGenics Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CardioGenics Holdings from 6/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/6/2024.

When did CardioGenics Holdings pay the last dividend?

The last dividend was paid out on 6/6/2024.

What was the dividend of CardioGenics Holdings in the year 2023?

In the year 2023, CardioGenics Holdings distributed 0 USD as dividends.

In which currency does CardioGenics Holdings pay out the dividend?

The dividends of CardioGenics Holdings are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von CardioGenics Holdings

Our stock analysis for CardioGenics Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CardioGenics Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.